Table 1. Characteristics of studies included in meta-analysis.
| Author (year) | Country | Type of study | Sample size, n: CRPA vs. CSPA | Sites of infection | Definition of resistance | Type of carbapenem | Carbapenem Resistance | NOS score |
|---|---|---|---|---|---|---|---|---|
| Krcmery (1996)15 | Slovakia | Retrospective cohort | 10 vs. 91 | Bacteremia | NA | Imipenem | 9.9% | 5 |
| Cofsky (2002)16 | USA | Retrospective case-control | 10 vs. 10 | Any infection | NA | Carbapenem | NA | 9 |
| Kang (2005)17 | Korea | Retrospective cohort | 28 vs. 162 | Bacteremia | NCCLS | Imipenem | 14.7% | 7 |
| Marra (2005)18 | USA | Retrospective cohort | 16 vs. 72 | Bacteremia | NA | Imipenem | 18.2% | 7 |
| Gasink (2006)8 | USA | Retrospective cohort | 872 | Any infection or colonization | NCCLS | Imipenem | NA | 7 |
| Lautenbach (2006)19 | USA | Retrospective cohort | 135 vs. 719 | Any infection or colonization | CLSI | Imipenem | 15.8% | 7 |
| Eagye (2009)20 | USA | Retrospective case-control | 58 vs. 125 | Any infection or colonization | NA | Meropenem | NA | 9 |
| Lautenbach (2010)21 | USA | Retrospective cohort | 253 vs. 2289 | Any infection or colonization | CLSI | Imipenem | 10.0% | 9 |
| Suárez (2010)22 | Spain | Retrospective cohort | 33 vs. 88 | Bacteremia | CLSI (2005) | Carbapenem | 27.3% | 9 |
| Joo (2011)13 | Korea | Retrospective cohort | 46 vs. 156 | Bacteremia | NA | Imipenem | 22.8% | 9 |
| Babu (2011)23 | India | Prospective cohort | 24 vs. 86 | Any infection | CLSI (2007) | Imipenem | 21.8% | 5 |
| Pena (2012)24 | Spain | Prospective cohort | 145 vs. 487 | Bacteremia | CLSI | Carbapenem | 22.9% | 9 |
| Tuon (2012)25 | Brazil | Retrospective cohort | 29 vs.48 | Bacteremia | CLSI (2010) | Carbapenem | 37.7% | 9 |
| Hattemer (2013)14 | USA | Retrospective cohort | 13 vs. 137 | Bacteremia | CLSI (2012) | Carbapenem | 8.7% | 9 |
| Lin (2014)26 | China | Retrospective case-control | 82 vs. 82 | Any infection or colonization | CLSI (2011) | Carbapenem | NA | 7 |
| Dantas (2014)27 | Brazil | Retrospective cohort | 55 vs. 65 | Bacteremia | CLSI | Carbapenem | 45.8% | 7 |
| Kim (2014)28 | Korea | Retrospective cohort | 118 vs. 116 | Bacteremia | CLSI (2008) | Carbapenem | 50.4% | 9 |
Abbreviations: CRPA, carbapenem-resistant Pseudomonas aeruginosa; CSPA, carbapenem-susceptible Pseudomonas aeruginosa; NOS, Newcastle-Ottawa Scale; NA, not available; NCCLS, National Committee for Clinical Laboratory Standards; CLSI, Clinical and Laboratory Standard Institute.